预约演示
Genfit adds 3rd liver failure asset to roster in $107M biobucks deal with Seal Rock
2023-06-01
临床1期引进/卖出临床2期
Genfit now has three candidates aimed at acute-on-chronic liver failure.
Genfit has added a third liver failure caacute-on-chronic liver failureesy of a licensing deal with Seal Rock Therapeutics potentially worth up to 100 million euros ($107 million) in biobucks.
Genfitset in question is liver failure form of Seal Rock’s ASK1 inhibitor SRT-015, for which Genfit Seal Rock Therapeutics in liver disease. France-based Genfit has its sights set on entering the clinic with the candidate in the second half of next year, with a proof-of-concept study in acute-on-chronic liver failure (ACLF) penciled in for 2025.
Apoptosis signal-regulating kinase 1 (ASK1) is a member of ASK1 inhibitorASK1MAP kinase SRT-015 Inhibiting Genfitas been shown to block lipoliver diseasee-associated hyGenfitlammatory response as well as reduce the release of proinflammatory cytokines, reduce fibrosis and protect macrophage mitochondracute-on-chronic liver failure (ACLF) postmarket release yesterday.
These drugs haven’t always lived up to the hype, however. Gilead’s ASK1 inhibitor selonsertib flunked aorgan diseasesse 3 trials in nonalcoholic steatohepatitis, the same condition for which Seal Rock had been developing SRT-015.
Eyeing an ACLF market estimated to total $4 billion in theGileadandASK1 inhibitorASK1e major Eurselonsertibries alone, the Seal Rock deal means Genonalcoholic steatohepatitiss targeting this space. Those include VS-01, which is in a phSRT-015rial for adults with ACLF grades 1 and 2 and ascites, as well as NTZ, which has completed a pair of phase 1 studies in renal and hepatic impairment. Genfit is now readying NTZ for a phase 2 in ACLF.
Genfitis a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strliver diseasesadership in this indication,” Prigent added. “Considering its liver-centric activity, the potential for multi-organ benefits and the breadth of evidence supporting further development in ACLF, we strongly believe in the potential of SRT-015.”
Genfit’s remaining therapeutic pipeline includes the dual PPAR agonist elafibranor, which is undergoing late-stage studies for primary biliary cholangitis and has been licensed by Ipsen. There's also GNS561, a PPT1 inhibitor that has previously completed a phase 1 trial and is now being developed for bile duct cancer, and VS-02, a preclinical urease inhibitor the biotech hopes to progress for hepatic encephalopathy.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。